trial · primary record
Brentuximab Vedotin
Classic Hodgkin Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 62 |
| Primary completion | 2027-02-25 |
| Primary endpoint | Progression-free Survival at 18 Months |
| Registry ID | NCT03057795 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:51.439Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03057795
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.